1075 - Modifying small molecule HIV-1 viral entry inhibitors to bind glycoprotein gp120 on a solid surface
Stephen G Tajc, Cara R Czechowski, firstname.lastname@example.org. Department of Chemistry, Nazareth College, Rochester, NY, United States
According to the World Health Organization, 34 million people are currently living with HIV1. Small molecule HIV viral entry inhibitor drugs are interesting compounds as they target protein complexes involved in viral membrane fusion that could be used for HIV diagnostics. The small molecule drug BMS-806 binds to the HIV-1 envelope glycoprotein gp120 and is a potent HIV-1 viral entry inhibitor2. In this research we explore adding a synthetic linker using solid surface techniques to BMS-806 focusing on the portion of 7-azaindole with amine molality. The linker on BMS-806 will then allow for solid surface binding analysis with gp120. These studies will provide further insight of HIV-1 viral protein interactions with small molecules.
1. 2012. Global Summary of the HIV/AIDS epidemic, December 2010. http://www.who.int/hiv/data/en/. 2012 April 12.
2. Lin P, Blair W, Wang T, Spicer T, Guo Q, Zhou N, Gong Y, Heidi W, Rose R, Yamanaka G, et al. 2003. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. PNAS. 100(19):11013-11018.
Monday, April 8, 2013 12:00 PM
Undergraduate Research Posters (12:00 PM - 02:30 PM)
Location: Morial Convention Center
Room: Hall D